Figure 5
From: E2F4 regulatory program predicts patient survival prognosis in breast cancer
Application of the E2F4 signature for predicting patient survival times in different histological subtypes. Note that E2F4 signature is effective in ER+ but not in ER- samples (A), in PR+ but not in PR- samples (B), and in low MYC but not in high MYC samples (C). ER, estrogen receptor; PR, progesterone receptor.